Clinical trial
A Prospective, Phase 4, Multicenter, Open-label Pilot Study of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines
NCT07421544 is registered in ClinicalTrials.gov with Goldman, Butterwick, Fitzpatrick and Groff as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Phase 4, Multicenter, Open-label Pilot Study of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines
- Lead sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- March 1, 2026
- Completion date
- July 1, 2026
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
facial laxity, fine lines, volume loss, wrinkle